Shares of Roche drew increased retail attention Monday after the Swiss drugmaker said it would move its investigational ...

Venclexta, when combined with azacitidine, elicited an overall survival benefit below 10% in patients with myelodysplastic ...

The Swiss drugmaker said it was “encouraged” by the signs of effectiveness of the drug, developed by biotech Prothena, showed ...

Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click ...

Roche and Prothena are forging ahead to late-stage studies for their investigational Parkinson’s disease antibody ...

Basel: Roche has announced its decision to proceed with Phase III development of prasinezumab, an investigational ...

Roche discontinued the commercial and clinical use of Elevidys after two cases of fatal acute liver failure. The Swiss ...

Roche and AbbVie have once again come up short in their attempt to gain an additional indication for their blockbuster blood ...

Roche (SIX:ROG) shares dropped 2% on Monday after the company paused dosing of its gene therapy Elevidys in non-ambulatory ...

Roche to advance prasinezumab into phase III development for early-stage Parkinson's disease: Basel Tuesday, June 17, 2025, 09:00 Hrs [IST] Roche announced its decision to proceed ...